Pure Biologics Spólka Akcyjna (PUR.WA)
PLN 15.22
(-8.86%)
PLN 15.22
(-8.86%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.26 Million | -17.38 Million | -24.03 Million | -1.35 Million | 5.33 Million | -2.48 Million |
| Net Income | -35.69 Million | -25.6 Million | -11.76 Million | -11.75 Million | -4.54 Million | -689.34 Thousand |
| Depreciation & Amortization | 5.78 Million | 2.49 Million | 2.92 Million | 3.11 Million | 732.22 Thousand | 210.67 Thousand |
| Deferred income taxes | - | - | 34 Thousand | -147 Thousand | -9999.05 | - |
| Stock-based compensation | 1.3 Million | 4.41 Million | 2.78 Million | 3.75 Million | 10 Thousand | - |
| Change in working capital | -4.49 Million | 333 Thousand | -18.23 Million | 3.34 Million | 8.96 Million | -2.02 Million |
| Other non-cash items | 3.55 Million | 973 Thousand | 227 Thousand | 349 Thousand | 180.12 Thousand | 15.1 Thousand |
| Investing Cash Flow | 391 Thousand | 15.34 Million | -28.47 Million | -561 Thousand | -161.91 Thousand | -162.15 Thousand |
| Investments in PPE | -176 Thousand | -5.75 Million | -673 Thousand | -561 Thousand | -161.91 Thousand | -162.15 Thousand |
| Acquisitions | - | 25.93 Million | -15 Thousand | - | - | - |
| Investment purchases | -3.99 Million | -4.88 Million | -36.04 Million | - | - | - |
| Sales/Maturities of investments | 4.91 Million | 25.94 Million | 8.24 Million | - | - | - |
| Other Investing Activities | 567 Thousand | -25.88 Million | 6000.00 | - | - | - |
| Financing Cash Flow | 24.21 Million | -1.87 Million | 49.73 Million | -3.05 Million | 8.55 Million | 2.57 Million |
| Debt repayment | -12 Million | -1.54 Million | -2.14 Million | -2.7 Million | -144.33 Thousand | -61.16 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 18.86 Million | - | 52.11 Million | - | 9.54 Million | 2.7 Million |
| Other Financing Activities | 15.75 Million | -329 Thousand | -227 Thousand | -349 Thousand | -843.29 Thousand | -59.39 Thousand |
| Accounts receivables | 202 Thousand | -5.92 Million | -7.93 Million | -339 Thousand | 1.43 Million | -455.04 Thousand |
| Accounts payables | - | 7.65 Million | -3.19 Million | 1.79 Million | 334 Thousand | 1.83 Million |
| Inventory | - | - | -34 Thousand | 91 Thousand | -91 Thousand | 32.67 Thousand |
| Other working capital | -6.65 Million | -1.39 Million | -7.07 Million | 1.79 Million | 7.29 Million | -2.05 Million |
| Cash at beginning of period | 2.25 Million | 6.17 Million | 8.95 Million | 13.92 Million | 195.93 Thousand | 267.04 Thousand |
| Cash at end of period | 3.6 Million | 2.25 Million | 6.17 Million | 8.95 Million | 13.92 Million | 196.88 Thousand |
| Capital Expenditure | -176 Thousand | -5.75 Million | -673 Thousand | -561 Thousand | -161.91 Thousand | -162.15 Thousand |
| Effect of forex changes on cash | - | -1000.00 | - | - | 0.64 | - |
| Net cash flow / Change in cash | 1.34 Million | -3.91 Million | -2.77 Million | -4.96 Million | 13.72 Million | -70.16 Thousand |
| Free Cash Flow | -23.43 Million | -23.14 Million | -24.7 Million | -1.91 Million | 5.17 Million | -2.65 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.99 Million | -4.97 Million | -11.13 Million | -35.69 Million | -7.59 Million | -9.91 Million |
| Depreciation & Amortization | -111 Thousand | 265 Thousand | 1.41 Million | 5.78 Million | 1.39 Million | 1.51 Million |
| Deferred income taxes | - | - | - | - | - | 585 Thousand |
| Stock-based compensation | - | - | 1.3 Million | 1.3 Million | - | 655 Thousand |
| Change in working capital | -4.33 Million | 6.48 Million | -981 Thousand | -4.49 Million | -1.27 Million | -1.45 Million |
| Other non-cash items | -101 Thousand | -6.15 Million | 1 Million | 3.55 Million | 631 Thousand | 669 Thousand |
| Investing Cash Flow | 2.28 Million | -11 Thousand | -372 Thousand | 391 Thousand | 8.15 Million | -3.03 Million |
| Investments in PPE | - | -85 Thousand | - | -176 Thousand | -51 Thousand | 17 Thousand |
| Acquisitions | - | 74 Thousand | - | - | -8.2 Million | -4.92 Million |
| Investment purchases | - | - | -2000.00 | -3.99 Million | 8.2 Million | -3.04 Million |
| Sales/Maturities of investments | - | - | 4.91 Million | 4.91 Million | 8.2 Million | 4.91 Million |
| Other Investing Activities | 2.28 Million | 74 Thousand | -372 Thousand | 567 Thousand | 1000.00 | -3.04 Million |
| Financing Cash Flow | 155 Thousand | -346 Thousand | 833 Thousand | 24.21 Million | -2.73 Million | 9.8 Million |
| Debt repayment | -125 Thousand | -125 Thousand | -200 Thousand | -12 Million | -135 Thousand | -65 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 18.86 Million | - | - |
| Other Financing Activities | 30 Thousand | -301 Thousand | -563 Thousand | 15.75 Million | -2.59 Million | 9.86 Million |
| Accounts receivables | 328 Thousand | 4.84 Million | 2.49 Million | 202 Thousand | 262 Thousand | -880 Thousand |
| Accounts payables | - | 2.09 Million | - | - | 294 Thousand | 1.2 Million |
| Inventory | - | - | - | - | 310 Thousand | -120 Thousand |
| Other working capital | -4.66 Million | -457 Thousand | -1.93 Million | -6.65 Million | -2.13 Million | -1.66 Million |
| Cash at beginning of period | 5.29 Million | 6.62 Million | 6.62 Million | 2.25 Million | 8.05 Million | 9.23 Million |
| Cash at end of period | 192 Thousand | 5.29 Million | 3.6 Million | 3.6 Million | 6.62 Million | 8.05 Million |
| Capital Expenditure | - | -85 Thousand | - | -176 Thousand | -51 Thousand | 17 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | 1000.00 |
| Net cash flow / Change in cash | -5.09 Million | -1.33 Million | -3.02 Million | 1.34 Million | -1.42 Million | -1.18 Million |
| Free Cash Flow | -7.53 Million | 1.95 Million | -3.48 Million | -23.43 Million | -6.89 Million | -7.93 Million |
JAGSNPHARM
G1A
JROOF
GGP
NXC
AKZOY